RE:I have a 40 page LABS research / valuation report available cred:danny deadlock
https://microcap.com/pdf I have a 40 page LABS research / valuation report available
I have been picking away at this report since summer but wanted to see the lawsuit settled and what Q3 financials would look like. While I wish I could have arrived at a higher "current" valuation (12 to 14 cents), it is difficult with the state of the industry and microcap stocks in general - which have been dismal for two years now.
However, after seeing Q3 progress, I remain very confident / bullish for 2024 and if they can achieve break-even next year, I believe 19 to 25 cents is fair value. There are several catalysts that would provide "blue sky" potential, but that is not something a person should bank on.
Even at 12 to 14 cents, that is a solid gain from 7 cents. And 19 to 25 cents seems very realistic and would provide a great 12 to 18 month gain. I am turning my MicroCap.com site into an educational site for penny stock investors so as a shareholder this worked well as I was able to prepare a research report on a very good company that demonstrates what is required to complete "proper" due diligence on a company.
A Forty page report is excessive but Medipharm has a lot of irons in the fire and I enjoyed the "deep dive". I likely went too far down the rabbit hole, but I believe I covered most everything.
If you are a shareholder, I would encourage you to share the report (or link to the report). Good companies like this struggle to get analyst coverage so it's often up to the shareholders to "tell their story". The more potential investors we have that can understand this story and its potential, the better chance of achieving a "fair valuation" that will help when the time comes for them to consider mergers or acquisitions (saves excess dilution).
You can find the report on my MicroCap website - https://microcap.com/pdf